The World Health Organization (WHO) esti mates that approximately 1.3 billion people live with some form of vision impairment. Degenerative diseases of the retina, such as agerelated macular degeneration (AMD) and inherited retinal dystrophies (IRDs), are major causes of untreatable blindness, with glauco ma, pathological myopia, and corneal blind ness also having a major health impact (1) . Recent clinical trials have led to approval in 2017 of the first treatment, gene therapy, for treating blinding retinal degeneration. This follows decades of research on visual pro cessing, genetics, animal models, mecha nisms of vision loss, vector design, imaging, and microsurgery that have provided invaluable preclinical data and clinical proofofconcept results. Substantial investment by charities, public agencies, and businesses has moved innovative therapeutic strategies, such as pharmacotherapy, gene therapy, stem cell therapy, and optogenetics, into clinical de velopment. In this Focus article, celebrating Science Translational Medicine's 10th anni versary, we examine some of the exciting advances-from gene and cell therapy to pros thetics and neuroprotection-made in treating retinal degeneration over the past decade.
Progress in ophthalmology is intrinsically linked to increased understanding of the mor phology and function of the visual system. Vision is a complex process that begins in the retina, the specialized neurosensory organ that is established in the eye during embryonic development (2) . Retinal photoreceptor cells (rods and cones) convert light into neuronal signals that are processed by other retinal cell types including retinal ganglion cells. The resulting visual information travels via the op tic nerve to higher centers in the brain, where it is processed and decoded into visual per ception. Specific characteristics make the eye particularly suited for diagnostic and thera peutic exploration: easy access, small volume, high internal compartmentalization, and stable cell populations. The optical transparency of the eye allows direct visualization with high resolution imaging and precise evaluation of disease stage and response to therapy. More over, the relative immune privilege of the eye, especially the subretinal space, reduces ad verse responses to injected vectors and gene products. However, the impact of this im mune privilege on cellbased therapies is less clear.
AMD is a leading cause of irreversible blindness and central vision loss in the elderly (Fig. 1) . It is a multifactorial disease in which cumulative damage over a lifetime leads to progressive deterioration of key retinal struc tures, including the retinal pigment epithelium (RPE), Bruch's membrane, the choroid, and photoreceptor cells. Although there has been substantial progress in treating the neovas cular form of AMD (characterized by growth of abnormal, leaky blood vessels), there is no effective or approved treatment for the atrophic "nonneovascular" form (associated with gradual loss of photoreceptors and RPE cells). Oxidative stress, inflammation, heredity, environmental factors, and demographic factors are implicated in AMD etiology but not fully understood and are potential therapeutic targets. Despite continued gains in under standing AMD pathophysiology, relevant animal models and prospective controlled clinical studies are lacking. Furthermore, early markers of the disease that could be targets of future preventive treatment have yet to be identified or validated.
IRDs may be inherited as Mendelian traits or through mitochondrial DNA, involve the entire retina or just the macula, affect either rod or cone photoreceptor cells predomi nantly, and may occur as single, syndromic, or systemic forms, with peripheral and central loss of vision (Fig. 1) . The numerous challenges associated with the development of therapies should be considered alongside the extensive genetic and phenotypic heterogeneity of IRDs. In addition, genotypephenotype correlations are difficult: Different mutations in the same gene can cause different diseases, or the same mutation can result in different phenotypes.
THERAPEUTIC STRATEGIES FOR TREATING BLINDING DISEASES
There have been some notable successes over the past decade using gene replacement strat egies for treating blinding retinal diseases. Leber congenital amaurosis (LCA) is the most severe IRD that usually develops in early childhood. In the autosomalrecessive form of LCA caused by RPE65 mutations, a bio chemical deficit impairs the ability of photo receptor cells to respond to light. Delivery of wildtype RPE65 complementary DNA (cDNA) to RPE target cells in animal models and in humans led to substantial improve ments in light sensitivity, visual fields, and functional vision as demonstrated on multi luminance mobility testing. These studies led to regulatory approval in 2017 for gene therapy to treat LCA in children and adult patients with confirmed biallelic RPE65 mutationassociated retinal dystrophy (3). The successes with RPE65 gene therapy have paved the way for more than 30 gene replacement trials worldwide. Phase 3 trials of gene replacement therapy for choroideremia, achromatopsia, and Leber hereditary optic neuropathy are ongoing. A recent promising strategy delivered an antisense oligonucleotide to restore correct splicing of a common LCAcausing variant, CEP290, that results in a splicing defect (4).
Geneindependent strategies could over come the complexities of the mechanisms underlying photoreceptor cell degeneration in AMD and the genetic heterogeneity of IRDs and their often dominant transmission. Of these strategies, neuroprotection aims to prevent or slow the progressive degeneration of photoreceptor cells. The retinaspecific neurotrophic factor rodderived cone viability factor rescued cone structure and function independently of genetic mutations and the mechanisms and extent of rod degeneration. This is a potential therapeutic strategy for a broad spectrum of retinal dystrophies (5). Stem cells are at the center of another mutationindependent approach for vision restoration that replaces degenerated cells. The proposed cell therapies are based on human pluripotent stem cells (PSCs), which expand indefinitely in culture and are a poten tially unlimited source of retinal cells (RPE cells, photoreceptor cells, and retinal ganglion cells) for cell replacement. Methods to differentiate human PSCs toward retinal lineages have im proved in the past decade, particularly the devel opment of threedimensional culture systems for generating human retinal organoids. Based on preclinical data, several stem cell-based therapies for RPE replacement for AMD and IRDs are currently under development or clin ical evaluation (6) . Stem cell therapy could be used to restore vision in a wide range of retinal degenerative conditions, provided that func tional integration into the host tissue occurs and that immune responses to transplanted cells can be avoided or limited.
TECHNOLOGICAL STRATEGIES FOR TREATING BLINDING DISEASES
Retinal prostheses are able to reactivate remain ing retinal circuits at the level of bipolar or ganglion cells after photoreceptor cell loss. Both epiretinal and subretinal implants are able to stimulate a lightinsensitive de generated retina and to restore partial vision in blind people (7, 8) . One implant has received market approval in Europe and in the United States; a photovoltaic wireless subretinal prosthesis is currently under clinical evaluation. The wireless device is characterized by photovoltaic electrodes with their own local return circuit and independent function (po tentially giving higher resolution) and a simpler surgical procedure than for wired implants.
Another technology called optoge netics makes cells light sensitive through expression of an optogene encoding a lightactivated channel or pump in the remaining inner retinal cells. Opto genes can be targeted to specific cell types using adenovirusassociated viral vectors equipped with cell type-specific promoters (9) . Optogenetic therapy could be used to resensitize a degenerated retina to visible light independent of the mu tation causing photoreceptor cell loss. Optogenes targeted to cones, bipolar cells, or ganglion cells in animal models of retinitis pigmentosa have been shown to restore visual function and behavioral responses to visual cues. Furthermore, efficient expression of optogenes in cones and ganglion cells has been demonstrated in the retina of nonhuman primates in vivo and in postmortem human retinas in vitro. The choice of the target cell type depends on the state of retinal degenera tion. Cone targeting is expected to pro duce optimal results, followed by targeting of bipolar cells and, lastly, ganglion cells. All of these approaches require the patients to wear goggles that stimulate the optogenes with appropriate light intensity. Ganglion cell-based optogenetic stimulation is in phase 1 clinical trials for treating advanced retinitis pigmentosa (ClinicalTrials.gov: NCT03326336).
ONGOING CHALLENGES AND FUTURE POTENTIAL
Recent therapeutic strategies for treating blindness are very encouraging, and the field is poised to address the next set of challenges. Efficiently timed delivery of genes or small molecules to the appropriate cells is critical for success. For developmental IRDs, maximum efficacy would likely require intervention II) . Neuroprotective strategies, particularly those for preserving cones, are the best approach for treating disease where there is ongoing photoreceptor cell degeneration (stage III). Neuroprotection of cones can stave off loss of high acuity vision by protecting the fovea (stage III). Stem cell therapy, optogenetic therapy, and retinal prostheses are used to restore vision during the later stages of retinal degeneration, after the loss of cone outer segments (stage III). These approaches can be applied independently of the causal mutation and are expected to restore a low degree of vision in blind patients (stage IV). Pierre-Auguste Renoir, "Madame Henriot," National Gallery of Art, Washington, DC.
during gestation, which is fraught with safe ty and ethical issues. The rescue of photore ceptor cell function also depends on whether there are any viable cells left in the retina; there may be nothing left to treat if the in tervention is too late. Remodeling of the ret ina late in disease may also limit the ability of therapies to restore retinal function. Retinal remodeling may also affect the feasibility of gene transfer through subretinal injection. Subretinal gene transfer requires general anesthesia and carries risks, making delivery through the routine office procedure of in travitreal injection appealing. However, there are very few gene delivery agents that can reach the appropriate cellular targets in an organ the size of the human eye after intravitreal delivery. Furthermore, some test compounds are un stable (antisense oligonucleotides), necessi tating repeated injections. Delivery of antisense oligonucleotides via a slowrelease compound may sustain the therapeutic effect and avoid the risk of repeated injections.
Several common IRD genes have relatively large cDNAs that are incompatible with the packaging constraints of the current set of viral vectors. Effective delivery will require, for example, developing vectors with a larger cargo hold, trimming the transgene cassettes, halving the cargo and delivering multiple com plementary drugs, and developing methods to safely and specifically edit the endogenous DNA or RNA. So far, clinical trials have not tar geted autosomaldominant mutations causing retinal degeneration. This may require delivery of two different reagents to inactivate the native faulty gene and deliver the normal gene. A geneediting approach for autosomaldominant IRDs, for example, would also require deliv ery of two different components, CRISPR and Cas9 (10) . Thus, from dosage, safety, and regulatory perspectives, gene transfer of large genes or genes for autosomaldominant retinal degenerative diseases is far more complicated than "simple" gene replacement.
The validation of a robust response to a therapeutic intervention can also be a challenge for diseases causing profoundly abnormal baseline vision. Traditionally, drugs for oph thalmic indications have been approved based on one criterion: the ability to read lines of letters on an eye chart. This standard reflects the function of the foveal cone cells that occupy 1/1000 of the area of the retina. Additional criteria are required to assess potential bene fits for aspects of vision carried out by the extrafoveal retina. National regulatory agen cies now request evaluation of the impact of disease and therapies on functional vision (patientreported outcomes, performance based tests, or daily activities).
IRDs and other diseases that affect gan glion cells can lead to atrophy of the optic nerve. Therapy cannot improve vision after optic nerve loss. However, brainmachine in terface technologies using electrode arrays or optogenetics can stimulate the visual pathway downstream of the retina. Electrical stimu lation of the primary visual cortex is one possible scenario that is currently in clinical trials. An early feasibility study is evaluating the safety of the visual cortical prosthesis and surgery, as well as the reliability of the sys tem and the usefulness of any restored vision (ClinicalTrials.gov: NCT03344848).
The expanding armamentarium of gene therapy and geneediting agents will allow testing of interventions for a variety of IRDs. As safety data accumulate on new vectors and routes of administration, regulatory bodies may relax the regulatory burden. This, in turn, will reduce the cost of clinical trials. Improved properties of therapeutics will allow many of them to be delivered safely during routine office procedures. As interventions specific to single genetic targets continue to develop, interventions that could treat IRDs regardless of genetic cause will also emerge. The latter include neuroprotective agents, those that en hance metabolic and nutritional pathways and those that can activate more distal neurons in the visual pathway. The next major chal lenges will be to understand the effects of such therapies on brain plasticity and to demon strate the impact of vision preservation or restoration in real life.
